Quantcast

Latest Bayer Schering Pharma AG Stories

2011-05-26 08:26:00

BURLINGAME, Calif., May 26, 2011 /PRNewswire/ -- Epitomics, Inc. announced today that it has signed a service agreement with Bayer Schering Pharma AG, Germany (Bayer HealthCare). Epitomics will use its proprietary rabbit monoclonal antibody technology to produce antibodies for Bayer HealthCare's drug target identification and validation. "Epitomics has had a long-standing experience with Bayer HealthCare. This new agreement is a major expansion of our collaboration and confirms the...

2010-12-08 14:47:00

SAN DIEGO, Dec. 8, 2010 /PRNewswire/ -- Prometheus Laboratories Inc., a specialty pharmaceutical and diagnostic company, announced today the execution of an oncology-focused mutational analysis services agreement with Bayer Schering Pharma AG, Germany, a worldwide leading pharmaceutical company. The addition of this mutational analysis services agreement broadens Bayer's oncology-focused molecular and pathway activation profiling collaboration with Prometheus to include comprehensive...

2010-09-29 06:00:00

CAMBRIDGE, Mass., Sept. 29 /PRNewswire/ -- Ligon Discovery, the innovator of Small Molecule Microarray technology, today announced that it has partnered with Bayer Schering Pharma AG, Germany, to apply its proprietary Small Molecule Microarray screening platform (SMM) to discover potential first-in-class drug candidates for new disease targets. Ligon's SMM technology offers a completely differentiated approach to the identification of valid drug leads for historically intractable...

2010-06-17 03:10:00

WAYNE, N.J., June 17 /PRNewswire/ -- Bayer Schering Pharma AG and OncoMed Pharmaceuticals, Inc., today announced a global strategic alliance to discover, develop and commercialize novel anti-cancer stem cell therapeutics targeting the Wnt signaling pathway. Cancer stem cells are a subset of tumor cells believed to play a significant role in the establishment, metastasis and recurrence of cancer and agents targeting the Wnt pathway have the potential to be developed as pan-tumor drugs....

2010-06-17 03:00:00

REDWOOD CITY, Calif., June 17 /PRNewswire/ -- OncoMed Pharmaceuticals, Inc. and Bayer Schering Pharma AG, Germany, today announced a global strategic alliance to discover, develop and commercialize novel anti-cancer stem cell therapeutics targeting the Wnt signaling pathway. Cancer stem cells are a subset of tumor cells believed to play a significant role in the establishment, metastasis and recurrence of cancer. The strategic alliance leverages OncoMed's leadership in cancer stem...

2010-05-05 06:30:00

BETHESDA, Md., May 5 /PRNewswire-FirstCall/ -- Micromet, Inc. (Nasdaq: MITI), a biopharmaceutical company focused on the development and commercialization of next-generation antibodies for the treatment of cancer, today announced its financial results for the first quarter ended March 31, 2010. "With the proceeds from our recent financing, we are well-positioned to conduct the planned European pivotal study of blinatumomab in patients with acute lymphoblastic leukemia and other studies...

2010-04-21 07:55:00

BETHESDA, Md., April 21 /PRNewswire-FirstCall/ -- Micromet, Inc. (Nasdaq: MITI) a biopharmaceutical company focused on the development and commercialization of next-generation antibodies for the treatment of cancer, announced today that it has achieved a milestone under its collaboration agreement with Bayer Schering Pharma AG. The milestone was triggered by Micromet's achievement of pre-clinical proof of concept for a BiTE antibody for the treatment of solid tumors. "We have made...

2010-04-08 16:00:00

WARRENDALE, Pa., April 8 /PRNewswire/ -- MEDRAD Interventional(TM)/Possis® today announced the initiation of a supply agreement with ev3 Inc. (Nasdaq: EVVV). Under terms of the agreement, MEDRAD will make available the Cotavance(TM) peripheral drug-eluting balloon angioplasty catheter with Paccocath® technology for study in combination with ev3's SilverHawk® and TurboHawk(TM) Plaque Excision Systems for use in the DEFINITIVE AR European...

2010-03-17 06:30:00

SAN DIEGO, March 17 /PRNewswire/ -- Prometheus Laboratories Inc., a specialty pharmaceutical and diagnostic company, today announced the execution of a research collaboration and license agreement with Bayer Schering Pharma AG, Germany, a worldwide leading specialty pharmaceutical company. The collaboration partners Prometheus' proprietary oncology diagnostic platform with Bayer's broad oncology pipeline in an effort to stratify patients to appropriate drug candidates and potentially...

2010-01-28 07:00:00

BEDFORD, Mass., Jan. 28 /PRNewswire/ -- VisEn Medical Inc., a leader in fluorescence in vivo imaging from research through medicine, announced today that it has acquired the fluorescence imaging agent intellectual property portfolios and related technology platforms from Bayer Schering Pharma AG, Germany. The patent acquisition includes over 45 issued patents worldwide covering a wide range of fluorescence agent constructs and imaging methods, and consolidates VisEn's patent and...


Word of the Day
vermicular
  • Like a worm in form or movement; vermiform; tortuous or sinuous; also, writhing or wriggling.
  • Like the track or trace of a worm; appearing as if worm-eaten; vermiculate.
  • Marked with fine, close-set, wavy or tortuous lines of color; vermiculated.
  • A form of rusticated masonry which is so wrought as to appear thickly indented with worm-tracks.
This word ultimately comes from the Latin 'vermis,' worm.
Related